Figure 2: Therapeutic Approach Based on Subtype and Sensitivity

ER/PR-positive
- Bone/Soft tissue: Hormonal Therapy
- Visceral/Low Volume: Hormonal Therapy
- Visceral/High Volume/Rapid Progression: Chemotherapy

Her2-Overexpressing
- Anti-Her2 Alone
- Anti-Her2 + Chemotherapy
- Combination Anti-Her2

Hormone-Refractory Her2 Neg or Triple Neg
- Medically Stable: Single Agent Chemotherapy
- Visceral Crisis/Rapid Progression: Combination Chemotherapy
- Progression Beyond First Line: Consider Clinical Trial